

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-F
(400/132)

Serial No.

10/665,951



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

U.S. PATENT APPLICATION DOCUMENTS

| Examiner Initial | | Document Number | Filing Date | Name | Class | Subclass | Publication Date if Appropriate |
|------------------|---|-----------------|-------------|-----------------------|-------|----------|---------------------------------|
| AB | * | 09/226,044 | 07/12/01 | Hoffman et al. | | | |
| | * | 10/151,116 | 05/17/02 | Matulic-Adamic et al. | | | |
| | * | 10/201,394 | 08/13/01 | Vargeese et al. | | | |
| | * | 10/287,949 | 11/04/02 | Pavco | | | |
| | * | 10/306,747 | 11/27/02 | Pavco | | | |
| | * | 10/427,160 | 04/30/03 | Vargeese et al. | | | |
| | * | 10/438,493 | 05/15/03 | Pavco et al. | | | |
| | * | 10/444,853 | 05/23/03 | McSwiggen et al. | | | |
| | * | 10/664,668 | 09/18/03 | McSwiggen et al. | | | |
| | * | 10/664,767 | 09/16/03 | McSwiggen et al. | | | |
| | * | 10/665,255 | 09/16/03 | McSwiggen et al. | | | |
| | * | 10/665,951 | 09/18/03 | McSwiggen et al. | | | |
| | * | 10/670,011 | 09/23/03 | McSwiggen et al. | | | |
| | * | 10/693,059 | 10/23/03 | McSwiggen et al. | | | |
| | * | 10/712,633 | 11/13/03 | McSwiggen et al. | | | |
| | * | 10/720,448 | 11/24/03 | McSwiggen et al. | | | |

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-F
(400/132)

Serial No.

10/665,951

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

| | | | | | | | |
|----|---|--------------|----------|------------------|--|--|--|
| AB | * | 10/727,780 | 12/03/03 | Vaish et al. | | | |
| | * | 10/757,803 | 01/14/04 | McSwiggen et al. | | | |
| | * | 10/758,155 | 01/12/04 | McSwiggen et al. | | | |
| | * | 10/764,957 | 01/26/04 | McSwiggen et al. | | | |
| | * | 10/831,620 | 04/23/04 | McSwiggen et al. | | | |
| | * | 2001/0007666 | 07/12/01 | Hoffman et al. | | | |
| | * | 2002/0130430 | 09/19/02 | Castor | | | |
| | * | 2004/0037780 | 02/06/04 | Parsons et al. | | | |
| | * | 60/082,404 | 04/20/98 | Thömspon et al. | | | |
| | * | 60/334,461 | 11/30/01 | Pavco | | | |
| | * | 60/358,580 | 02/20/02 | Beigelman et al. | | | |
| | * | 60/363,124 | 03/11/02 | Beigelman et al. | | | |
| | * | 60/386,782 | 06/06/02 | Beigelman et al. | | | |
| | * | 60/393,796 | 07/03/02 | McSwiggen et al. | | | |
| | * | 60/399,348 | 07/29/02 | McSwiggen et al. | | | |
| | * | 60/402,996 | 08/13/02 | Usman et al. | | | |
| | * | 60/406,784 | 08/29/02 | Beigelman et al. | | | |
| | * | 60/408,378 | 09/05/02 | Beigelman et al. | | | |
| | * | 60/409,293 | 09/09/02 | Beigelman et al. | | | |

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-F
(400/132)

Serial No.

10/665,951

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

| | | | | | | | |
|----|---|------------|----------|------------------|--|--|--|
| AB | * | 60/440,129 | 01/15/03 | Beigelman et al. | | | |
| AB | * | 60/543,480 | 02/10/04 | Jadhav et al. | | | |

U.S. PATENT DOCUMENTS

| Examiner Initial | | Document Number | Date | Name | Class | Subclass | Filing Date if Appropriate |
|------------------|---|-----------------|----------|------------------|-------|----------|----------------------------|
| AB | * | 4,501,729 | 02/26/85 | Boucher et al. | | | |
| | * | 5,138,045 | 08/11/92 | Cook et al. | | | |
| | * | 5,214,136 | 05/25/93 | Lin et al. | | | |
| | * | 5,334,711 | 08/02/94 | Sproat et al. | | | |
| | * | 5,624,803 | 04/29/97 | Noonberg et al. | | | |
| | * | 5,627,053 | 05/06/97 | Usman et al. | | | |
| | * | 5,631,360 | 05/20/97 | Usman et al. | | | |
| | * | 5,670,633 | 09/23/97 | Cook et al. | | | |
| | * | 5,672,695 | 09/30/97 | Eckstein et al. | | | |
| | * | 5,716,824 | 02/10/98 | Beigelman et al. | | | |
| | * | 5,792,847 | 08/11/98 | Buhr et al. | | | |
| | * | 5,804,683 | 09/08/98 | Usman et al. | | | |
| | * | 5,814,620 | 09/29/98 | Robinson et al. | | | |

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|--|---------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant: McSwiggen et al. | |
| | | Filing Date: September 18, 2003 | Group: |

| | | | | | | | |
|----|---|-----------|----------|-----------------------|--|--|--|
| AB | * | 5,831,071 | 11/03/98 | Usman et al. | | | |
| | * | 5,854,038 | 12/29/98 | Sullenger et al. | | | |
| | * | 5,889,136 | 03/30/99 | Scaringe et al. | | | |
| | * | 5,898,031 | 04/27/99 | Crooke | | | |
| | * | 5,902,880 | 05/11/99 | Thompson | | | |
| | * | 5,998,203 | 12/07/99 | Adamic et al. | | | |
| | * | 6,001,311 | 12/14/99 | Brennen | | | |
| | * | 6,005,087 | 12/21/99 | Cook et al. | | | |
| | * | 6,008,400 | 12/28/99 | Scaringe et al. | | | |
| | * | 6,054,576 | 04/25/00 | Bellon et al. | | | |
| | * | 6,107,094 | 08/22/00 | Crooke | | | |
| | * | 6,111,086 | 08/29/00 | Scaringe et al. | | | |
| | * | 6,117,657 | 09/12/00 | Usman et al. | | | |
| | * | 6,146,886 | 11/14/00 | Thompson et al. | | | |
| | * | 6,153,737 | 11/28/00 | Manoharan et al. | | | |
| | * | 6,162,909 | 12/19/00 | Bellon et al. | | | |
| | * | 6,180,613 | 01/30/01 | Kaplitt et al. | | | |
| | * | 6,235,310 | 05/22/01 | Wang et al. | | | |
| | * | 6,248,878 | 06/19/01 | Matulic-Adamic et al. | | | |

| | |
|---------------------------------|--------------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|---------------------------------|--------------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-F
(400/132)

Serial No.

10/665,951

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

| | | | | | | | |
|----|---|-----------|----------|------------------|--|--|--|
| AB | * | 6,300,074 | 10/09/01 | Gold et al. | | | |
| | * | 6,303,773 | 10/16/01 | Bellon et al. | | | |
| | * | 6,335,434 | 01/01/02 | Guzaev et al. | | | |
| | * | 6,353,098 | 03/05/02 | Usman et al. | | | |
| | * | 6,362,323 | 03/26/01 | Usman et al. | | | |
| | * | 6,395,713 | 05/28/02 | Beigelman et al. | | | |
| | * | 6,437,117 | 08/20/02 | Usman et al. | | | |
| | * | 6,447,796 | 09/10/02 | Vook et al. | | | |
| | * | 6,469,158 | 10/22/02 | Usman et al. | | | |
| | * | 6,476,205 | 11/05/02 | Buhr et al. | | | |
| | * | 6,506,559 | 01/14/03 | Fire et al. | | | |
| | * | 6,528,631 | 03/04/03 | Cook et al. | | | |
| | * | 6,565,885 | 05/20/03 | Tarara et al. | | | |
| | * | 6,582,728 | 06/24/03 | Platz et al. | | | |
| | * | 6,586,524 | 07/01/03 | Sagara | | | |
| ✓ | * | 6,592,904 | 07/15/03 | Platz et al. | | | |

FOREIGN PATENT DOCUMENTS

| | | | | | | | Translation |
|--|--|----------|------|---------|-------|----------|-------------|
| | | Document | Date | Country | Class | Subclass | |

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-F
(400/132)

Serial No.

10/665,951

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

| | | Number | | | | | | |
|----|-----|-----------|----------|-----------------------|--|--|-----|----|
| | | | | | | | Yes | No |
| AB | 1. | 4037501 | 08/03/00 | AU (Kreutzer et al.) | | | | |
| | 2. | 2,359,180 | 08/03/00 | CA (Kreutzer et al.) | | | | |
| | 3. | 1144623 | 08/03/00 | EP (Kreutzer et al.) | | | | |
| | 4. | 89/02439 | 03/23/89 | WO (Arnold et al.) | | | | |
| | 5. | 90/14090 | 11/29/90 | WO (Gillespie et al.) | | | | |
| | 6. | 91/03162 | 03/21/91 | WO (Rossi et al.) | | | | |
| | 7. | 92/07065 | 04/30/92 | WO (Eckstein et al.) | | | | |
| | 8. | 93/15187 | 08/05/93 | WO (Usman et al.) | | | | |
| | 9. | 93/23569 | 11/25/93 | WO (Draper et al.) | | | | |
| | 10. | 94/02595 | 02/03/94 | WO (Sullivan et al.) | | | | |
| | 11. | 94/01550 | 01/20/94 | WO (Agrawal et al.) | | | | |
| | 12. | 95/06731 | 03/09/95 | WO (Usman et al.) | | | | |
| | 13. | 95/11910 | 05/04/95 | WO (Dudycz et al.) | | | | |
| | 14. | 96/10390 | 04/11/96 | WO (Ansell et al.) | | | | |
| | 15. | 96/10391 | 04/11/96 | WO (Choi et al.) | | | | |
| | 16. | 96/10392 | 04/11/96 | WO (Holland et al.) | | | | |
| | 17. | 96/18736 | 06/20/96 | WO (Beigelman et al.) | | | | |
| | 18. | 97/26270 | 07/24/97 | WO (Wincott et al.) | | | | |

EXAMINER

/Amy Bowman/

DATE CONSIDERED 06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MCDONNELL BOEHNIEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

The PTO did not receive the following
listed items(s) 4037501 (AU)

| | | | |
|---|--|--|---------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant: McSwiggen et al. | |
| | | Filing Date: September 18, 2003 | Group: |

| | | | | | | | | |
|----|-----|----------|----------|------------------------------------|--|--|--|--|
| AB | 19. | 98/13526 | 04/02/98 | WO (Woolf et al.) | | | | |
| | 20. | 99/07409 | 02/18/99 | WO (Deschamps de Paillette et al.) | | | | |
| | 21. | 99/14226 | 03/25/99 | WO (Wengel et al.) | | | | |
| | 22. | 99/31262 | 06/24/99 | WO (Barry et al.) | | | | |
| | 23. | 99/32619 | 07/01/99 | WO (Fire et al.) | | | | |
| | 24. | 99/49029 | 09/30/99 | WO (Graham et al.) | | | | |
| | 25. | 99/53050 | 10/21/99 | WO (Waterhouse et al.) | | | | |
| | 26. | 99/54459 | 10/28/99 | WO (Thompson et al.) | | | | |
| | 27. | 99/61631 | 12/02/99 | WO (Heifetz et al.) | | | | |
| | 28. | 00/01846 | 01/13/00 | WO (Plaetinck et al.) | | | | |
| | 29. | 00/44895 | 08/03/00 | WO (Kreutzer et al.) | | | | |
| | 30. | 00/44914 | 08/03/00 | WO (Li et al.) | | | | |
| | 31. | 00/49035 | 08/24/00 | WO (Sheen) | | | | |
| | 32. | 00/53722 | 09/14/00 | WO (O'Hare et al.) | | | | |
| | 33. | 00/63364 | 10/26/00 | WO (Pachuk et al.) | | | | |
| | 34. | 00/66604 | 11/09/00 | WO (Wengel et al.) | | | | |
| | 35. | 01/04313 | 01/18/01 | WO (Satishchandran et al.) | | | | |
| | 36. | 01/29058 | 04/26/01 | WO (Mello et al.) | | | | |
| | 37. | 01/36646 | 05/25/01 | WO (Zernicka-Goetz et al.) | | | | |

| | |
|---------------------------------|--------------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|---------------------------------|--------------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|--|---------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant: McSwiggen et al. | |
| | | Filing Date: September 18, 2003 | Group: |

| | | | | | | | | |
|----|-----|-----------|----------|--------------------------|--|--|--|--|
| AB | 38. | 01/38551 | 05/31/01 | WO (Grossniklaus et al.) | | | | |
| | 39. | 01/42443 | 06/14/01 | WO (Churikov et al.) | | | | |
| | 40. | 01/49844 | 07/12/01 | WO (Driscoll et al.) | | | | |
| | 41. | 01/53475 | 07/26/01 | WO (Cogoni et al.) | | | | |
| | 42. | 01/68836 | 09/20/01 | WO (Beach et al.) | | | | |
| | 43. | 01/70944 | 09/27/01 | WO (Honer et al.) | | | | |
| | 44. | 01/70949 | 09/27/01 | WO (Graham et al.) | | | | |
| | 45. | 01/72774 | 10/04/01 | WO (Deak et al.) | | | | |
| | 46. | 01/75164 | 10/11/01 | WO (Tuschl et al.) | | | | |
| | 47. | 01/92513 | 12/06/01 | WO (Arndt et al.) | | | | |
| | 48. | 01/96584 | 12/20/01 | WO (Mushegian et al.) | | | | |
| | 49. | 02/055692 | 07/18/02 | WO (Kreutzer et al.) | | | | |
| | 50. | 02/055693 | 07/18/02 | WO (Kreutzer et al.) | | | | |
| | 51. | 02/22636 | 03/21/02 | WO (Bennett et al.) | | | | |
| | 52. | 02/38805 | 05/15/02 | WO (Echeverri et al.) | | | | |
| | 53. | 02/44321 | 06/06/02 | WO (Tuschl et al.) | | | | |
| | 54. | 02/096927 | 12/05/02 | WO (Pavco) | | | | |
| | 55. | 03/24420 | 03/27/03 | WO (Alheim et al.) | | | | |
| V | 56. | 03/46185 | 06/05/03 | WO (Wang et al.) | | | | |

| | |
|---------------------------------|-----------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|---------------------------------|-----------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|--|---------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant: McSwiggen et al. | |
| | | Filing Date: September 18, 2003 | Group: |

| | | | | | | | | |
|----|-----|----------------|----------|-----------------------|--|--|--|--|
| AB | 57. | 03/47518 | 06/12/03 | WO (Wang et al.) | | | | |
| | 58. | PCT/US02/15876 | 05/20/02 | Beigelman et al. | | | | |
| | 59. | PCT/US02/17674 | 05/29/02 | WO (Pavco et al.) | | | | |
| | 60. | PCT/US03/05022 | 02/20/03 | WO (McSwiggen et al.) | | | | |
| | 61. | PCT/US03/05028 | 02/20/03 | McSwiggen et al. | | | | |
| | 62. | PCT/US03/05346 | 02/20/03 | McSwiggen et al. | | | | |
| | 63. | WO 03/064625 | 02/03/03 | WO (Woolf et al.) | | | | |
| | 64. | WO 03/064626 | 02/03/03 | WO (Woolf et al.) | | | | |
| | 65. | WO 03/030989 | 04/17/03 | WO (Behar et al.) | | | | |
| ↓ | 66. | WO 03/043689 | 05/03/03 | WO (Behar et al.) | | | | |
| | 67. | WO 04/013280 | 05/26/03 | WO (Davidson et al.) | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

| | | |
|----|-----|---|
| AB | 68. | Adah et al., "Chemistry and Biochemistry of 2',5'-Oligoadenylate-Based Antisense Strategy," <i>Current Medicinal Chemistry</i> , 8, 1189-1212 (2001) |
| ↓ | 69. | Aiello et al., "Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders," <i>The New England Journal of Medicine</i> 331(22):1480-1487 (1994) |
| ↓ | 70. | Akhtar and Juliano, "Cellular Uptake and Intracellular Fate of AntiSense Oligonucleotides," <i>Trends Cell Biol.</i> 2:139-144 (1992) |
| ↓ | 71. | Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <i>Nucleic Acids Research</i> 26:4910-4916 (1998) |

| | |
|---------------------------------|--------------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|---------------------------------|--------------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.


| | | | |
|---|--|---|-------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Att. Docket No. | Serial No. |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | 02-742-F (400/132) | 10/665,951 |
| | | Applicant: McSwiggen et al. | |
| | | Filing Date: September 18, 2003 | Group: |

| | | |
|----|-----|--|
| AB | 72. | Allshire, "RNAi and Heterochromatin - A Hushed-up Affair," <i>Science</i> 297:1818-1819 (2002) |
| | 73. | Andrews and Faller, "A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells," <i>Nucleic Acids Research</i> 19:2499 (1991) |
| | 74. | Autiero et al., "Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1," <i>Nature Medicine</i> , 9:936-943 (2003) |
| | 75. | Baenziger and Fiete, "Galactose and N-Acetylgalactosamine-Specific Endocytosis of Glycopeptides by Isolated Rat Hepatocytes," <i>Cell</i> 22:611-620 (1980) |
| | 76. | Bahramian et al., "Transcriptional and Posttranscriptional Silencing of Rodent $\alpha 1(I)$ Collagen by a Homologous Transcriptionally Self-Silenced Transgene," <i>Molecular and Cellular Biology</i> , 274-283 (1999) |
| | 77. | Bannai et al., "Effect of Injection of Antisense of Oligodeoxynucleotides of GAD Isozymes into Rat Ventromedial Hypothalamus on Food Intake and Locomotor Activity," <i>Brain Research</i> 784:305-315 (1998) |
| | 78. | Bannai et al., "Water-absorbent Polymer as a Carrier for a Discrete Deposit of Antisense Oligodeoxynucleotides in the Central Nervous System," <i>Brain Research Protocols</i> 3:83-87 (1998) |
| | 79. | Bass, "The short answer," <i>Nature</i> 411:428-429 (2001) |
| | 80. | Bass, "Double-Stranded RNA as a Template for Gene Silencing," <i>Cell</i> , 101, 235-238 (2000) |
| | 81. | Beaucage and Iyer, "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives," <i>Tetrahedron</i> 49:1925-1963 (1993) |
| | 82. | Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <i>The Journal of Biological Chemistry</i> 270:25702-25708 (1995) |
| | 83. | Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," <i>Nucleosides & Nucleotides</i> 16:951-954 (1997) |
| ✓ | 84. | Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis," <i>Bioconjugate Chem.</i> 8:204-212 (1997) |

| | |
|---------------------------------|--------------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|---------------------------------|--------------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|------------------------------------|------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. | Serial No. |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | 02-742-F (400/132) | 10/665,951 |
| | | | |
| | Applicant: McSwiggen et al. | | |
| | | Filing Date: September 18, 2003 | Group: |

| | | |
|---|-----|--|
| AB | 85. | Berkman et al., "Expression of the Vascular Permeability Factor/Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms," The Journal of Clinical Investigation, Inc. 91:153-159 (1993) |
| | 86. | Bernstein et al., "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference," Nature 409:363-366 (2001) |
| | 87. | Bettinger et al., "Size Reduction of Galactosylated PEI/DNA Complexes Improves Lectin-Mediated Gene Transfer into Hepatocytes," <i>Bioconjugate Chem.</i> , 10, 558-561 (1999) |
| | 88. | Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," Journal of Pharmaceutical Sciences 87:1308-1315 (1998) |
| | 89. | Boado, "Antisense drug delivery through the blood-brain barrier," Advanced Drug Delivery Reviews 15:73-107 (1995) |
| | 90. | Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," Biotechnology and Bioengineering (Combinatorial Chemistry) 61:33-45 (1998) |
| | 91. | Broaddus et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," J Neurosurg 88:734-742 (1998) |
| | 92. | Brody and Gold, "Aptamers as therapeutic and diagnostic agents," Reviews in Molecular Biotechnology 74:5-13 (2000) |
| | 93. | Burger et al., "Experimental Corneal Neovascularization: Biomicroscopic, Angiographic, and Morphologic Correlation," Cornea 4:35-41 (1985/1986) |
| | 94. | Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," Biochemistry 35:14090-14097 (1996) (volume no. mistakenly listed as 6) |
| | 95. | Burlina et al., "Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes," Bioorganic & Medicinal Chemistry 5:1999-2010 (1997) |
|  | 96. | Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," Methods in Enzymology 211:3-19 (1992) |

| | |
|------------------------------|-------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|------------------------------|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|--|---------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | | |
| | | Applicant: McSwiggen et al. | |
| | | Filing Date: September 18, 2003 | Group: |

| | | |
|----|------|---|
| AB | 97. | Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," <i>Nucleic Acids Research</i> 20:4581-4589 (1992) |
| | 98. | Chiu et al., "siRNA function in RNAi: A chemical modification analysis," <i>RNA</i> , 9:1034-1048 (2003) |
| | 99. | Choi et al., "Effect of Poly(ethylene glycol) Grafting on Polyethylenimine as a Gene Transfer Vector <i>in vitro</i> ," <i>Bull. Korean Chem. Soc.</i> , 22, 46-52 (2001) |
| | 100. | Chowrira et al., "In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," <i>J. Biol. Chem.</i> 269:25856-25864 (1994) |
| | 101. | Clark and Yoria, "Ophthalmic Drug Discovery," <i>Nature</i> , 2, 448-459 (2003) |
| | 102. | Clemens et al., "The Double-Stranded RNA-Dependent Protein Kinase PKR: Structure and Function," <i>J. Interferon & Cytokine Res.</i> , 17, 503-524 (1997) |
| | 103. | Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," <i>J. Am. Chem. Soc.</i> 113:6324-6326 (1991) |
| | 104. | Connolly et al., "Binding and Endocytosis of Cluster Glycosides by Rabbit Hepatocytes," <i>The Journ. of Biol. Chem.</i> 257:939-945 (1982) |
| | 105. | Conry et al., "Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration," <i>Clinical Cancer Research</i> 5:2330-2337 (1999) |
| | 106. | Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," <i>Trends In Genetics</i> 12:510-515 (1996) |
| | 107. | Detmar et al., "Overexpression of Vascular Permeability Factor/Vascular Endothelial Growth Factor and its Receptors in Psoriasis," <i>J. Exp. Med.</i> 180:1141-1146 (1994) |
| V | 108. | Diebold et al., "Mannose Polyethylenimine Conjugates for Targeted DNA Delivery into Dendritic Cells*," <i>The Journal of Biological Chemistry</i> , 274, 19087-19094 (1999) |

| | |
|---------------------------------|-----------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|---------------------------------|-----------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | | |
|--|--|---------------------|---------------------------------------|-------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | | Atty. Docket No. | Serial No. |
| | | | 02-742-F (400/132) | 10/665,951 |
| | | | Applicant: McSwiggen et al. | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Filing Date: | | Group: |
| | | September 18, 2003 | | |
| (Use several sheets if necessary) | | | | |

| | | |
|----|------|---|
| AB | 109. | Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," <i>Journal of Virology</i> 66:1432-1441 (1992) |
| | 110. | Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <i>Nucleic Acids Research</i> 18:6353-6359 (1990) [sometimes referred to as Seela and Kaiser] |
| | 111. | Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <i>Biopolymers</i> 48:39-55 (1998) |
| | 112. | Economides et al., "Cytokine traps: multi-component, high-affinity blockers of cytokine action," <i>Nature Medicine</i> , 9, 1, 47-52 (2003) |
| | 113. | Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> 411:494-498 (2001) |
| | 114. | Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila Melanogaster</i> Embryo Lysate," <i>The EMBO Journal</i> 20:6877-6888 (2001) |
| | 115. | Elbashir et al., "RNA Interference is Mediated by 21- and 22-Nucleotide RNAs," <i>Genes and Development</i> 15:188-200 (2001) |
| | 116. | Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in <i>Delivery Strategies for Antisense Oligonucleotide Therapeutics</i> , edited by Akhtar, CRC Press, pp. 17-220 (1995) |
| | 117. | Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," <i>Proc. Natl. Acad. Sci. USA</i> 87:6743-6747 (1990) |
| | 118. | Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <i>Cell Transplantation</i> 8:47-58 (1999) |
| ↓ | 119. | Epa et al., "Downregulation of the p75 Neurotrophin Receptor in Tissue Culture and <i>In Vivo</i> , Using β -Cyclodextrin-Adamantane-Oligonucleotide Conjugates," <i>Antisense Nuc. Acid Drug Dev.</i> , 10:469-478 (2000) |

| | |
|------------------------------|-----------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|------------------------------|-----------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | | |
|---|--|---|--|-------------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant: McSwiggen et al. | | |
| | | Filing Date: September 18, 2003 | Group: | |

| | | |
|----|------|---|
| AB | 120. | Erbacher et al., "Transfection and physical properties of various sacccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI), <i>The Journal of Gene Medicine</i> , 1, 210-222 (1999) [sometimes incorrectly cited as pages 1-18] |
| | 121. | Fava et al., "Vascular Permeability Factor/Endothelial Growth Factor (VPF/VEGF): Accumulation and Expression in Human Synovial Fluids and Rheumatoid Synovial Tissue," <i>J. Exp. Med.</i> 180:341-346 (1994) |
| | 122. | Ferentz and Verdine, "Disulfied Cross-Linked Oligonucleotides," <i>J. Am. Chem. Soc.</i> 113:4000-4002 (1991) |
| | 123. | Filleur et al., "SiRNA-mediated Inhibition of Vascular Endothelial Growth Factor Severely Limits Tumor Resistance to Antiangiogenic Thrombospondin-1 and Slows Tumor Vascularization and Growth," <i>Cancer Research</i> , 63, 3919-3922 (2003) |
| | 124. | Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <i>Nature</i> 391:806-811(1998) |
| | 125. | Fire, "RNA-triggered Gene Silencing," <i>TIG</i> 15:358-363(1999) |
| | 126. | Folkman et al., "Long-term Culture of Capillary Endothelial Cells," <i>Proc. Natl. Acad. Sci. USA</i> 76:5217-5221 (1979) |
| | 127. | Folkman, Judah, "Tumor Angiogenesis," <i>Advances in Cancer Research</i> 43:175-203 (1985) |
| | 128. | Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <i>Proc. Natl. Acad. Sci. USA</i> 83:9373-9377 (1986) [sometimes referred to as Frier] |
| | 129. | Furgeson et al., "Modified Linear Polyethylenimine—Cholesterol Conjugates for DNA Complexation," <i>Bioconjugate Chem.</i> , 14, 840-847 (2003) |
| | 130. | Futami et al., "Induction fo apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2," <i>Nucleic Acids Research Supplement</i> , 251-252 (2002) |
| | 131. | Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <i>Nucleic Acids Research</i> 21:2867-2872 (1993) |
| V | 132. | Genbank Accession No. AF020393 |

| | |
|-------------------------------------|-----------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|-------------------------------------|-----------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-F
(400/132)

Serial No.

10/665,951

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

| | | |
|----|------|--------------------------------|
| AB | 133. | Genbank Accession No. AF022375 |
| | 134. | Genbank Accession No. AF024710 |
| | 135. | Genbank Accession No. AF035121 |
| | 136. | Genbank Accession No. AF063657 |
| | 137. | Genbank Accession No. AF063658 |
| | 138. | Genbank Accession No. AF092125 |
| | 139. | Genbank Accession No. AF092126 |
| | 140. | Genbank Accession No. AF092127 |
| | 141. | Genbank Accession No. AF095785 |
| | 142. | Genbank Accession No. AF098331 |
| | 143. | Genbank Accession No. AF437895 |
| | 144. | Genbank Accession No. AF468110 |
| | 145. | Genbank Accession No. AF486837 |
| | 146. | Genbank Accession No. AH006909 |
| | 147. | Genbank Accession No. AJ000185 |
| | 148. | Genbank Accession No. AJ010438 |
| | 149. | Genbank Accession No. AY047581 |
| ✓ | 150. | Genbank Accession No. D89630 |
| | 151. | Genbank Accession No. E13256 |

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-F
(400/132)

Serial No.

10/665,951

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

| | | |
|----|------|--|
| AB | 152. | Genbank Accession No. E13332 |
| | 153. | Genbank Accession No. E14000 |
| | 154. | Genbank Accession No. E14233 |
| | 155. | Genbank Accession No. E15156 |
| | 156. | Genbank Accession No. E15157 |
| | 157. | Genbank Accession No. NM_002019 |
| | 158. | Genbank Accession No. NM_002020 |
| | 159. | Genbank Accession No. NM_002253 |
| | 160. | Genbank Accession No. NM_003376 |
| | 161. | Genbank Accession No. NM_003377 |
| | 162. | Genbank Accession No. NM_004469 |
| | 163. | Genbank Accession No. NM_005429 |
| | 164. | Genbank Accession No. U01134 |
| | 165. | Genbank Accession No. X62568 |
| | 166. | Genbank Accession No. X94216 |
| | 167. | Genbank Accession No. Y08736 |
| | 168. | Godbey et al., "Poly(ethylenimine) and its role in gene delivery," <i>Journal of Controlled Release</i> , 60, 149-160 (1999) |
| | 169. | Godbey et al., "Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery," <i>Proc. Natl. Acad. Sci. USA</i> , 96, 5177-5181 (1999) |
| | 170. | Gold et al., "Diversity of Oligonucleotide Functions," <i>Annu. Rev. Biochem.</i> 64:763-797 (1995) |

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|--|--|--|-------------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Applicant: | |
| (Use several sheets if necessary) | | McSwiggen et al. | |
| | | Filing Date: | Group: |
| | | September 18, 2003 | |

| | | |
|----|------|--|
| AB | 171. | Gonzalez et al., "New Class of Polymers for the Delivery of Macromolecular Therapeutics," Bioconjugate Chem. 10:1068-1074 (1999) |
| | 172. | Good et al., "Expression of small, therapeutic RNAs in human nuclei," Gene Therapy 4:45-54 (1997) |
| | 173. | Grant et al., "Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor," Diabetologia 36:282-291 (1993) |
| | 174. | Hall et al., "Establishment and Maintenance of a Heterochromatin Domain," Science 297:2232-2237 (2002) |
| | 175. | Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," Science, 286, 950-952 (1999) |
| | 176. | Hammond et al., "An RNA-Directed Nuclease Mediates Post-Transcriptional Gene Silencing in Drosophila Cells," Nature 404:293-296 (2000) |
| | 177. | Harborth et al., "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing," Antisense and Nucleic Acid Drug Development, 13:83-105 (2003) |
| | 178. | Hermann and Patel, "Adaptive Recognition by Nucleic Acid Aptamers," Science 287:820-825 (2000) |
| | 179. | Hofland and Huang, "Formulation and Delivery of Nucleic Acids," Handbook of Exp. Pharmacol. 137:165-192 (1999) |
| | 180. | Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods," VCH, 331-417 (1995) |
| | 181. | Hutvagner and Zamore, "A MicroRNA in a Multiple-Turnover RNAi Enzyme Complex," Science 297:2056-2060 (2002) |
| | 182. | Hutvagner et al., "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the let-7 Small Temporal RNA," Science 293:834-838 (2001) |
| ▼ | 183. | International Search Report for PCT/US03/05028 mailed October 17, 2003 |

| | | | |
|----------|--------------|-----------------|------------|
| EXAMINER | /Amy Bowman/ | DATE CONSIDERED | 06/08/2006 |
|----------|--------------|-----------------|------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|---|-------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. | Serial No. |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | 02-742-F (400/132) | 10/665,951 |
| | | Applicant: McSwiggen et al. | |
| | | Filing Date: September 18, 2003 | Group: |

| | | |
|----|------|--|
| AB | 184. | International Search Report for PCT/US03/05346 mailed October 17, 2003 |
| | 185. | Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," Chem. Pharm. Bull. 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet) |
| | 186. | Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," Science 229:345-352 (1985) |
| | 187. | Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," Tetrahedron Letters 34:301-304 (1993) (sometimes mistakenly referred to as Jsckhe) |
| | 188. | Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," Clinical Chemistry 45:1628-1650 (1999) |
| | 189. | Jenuwein, "An RNA-Guided Pathway for the Epigenome," Science 297:2215-2218 (2002) |
| | 190. | Jolliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," Fundam. Clin. Pharmacol. 13:16-26 (1999) |
| | 191. | Karle et al., "Differential Changes in Induced Seizures After Hippocampal Treatment of Rats with an Antisense Oligodeoxynucleotide to the GABA _A Receptor $\gamma 2$ Subunit," Euro. Jour. of Pharmacology 340:153-160 (1997) |
| | 192. | Karpeisky et al, "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," Tetrahedron Letters 39:1131-1134 (1998) |
| | 193. | Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," Antisense Research & Development 2:3-15 (1992) |
| | 194. | Kaspareit-Rittinghausen et al., "Animal Model of Human Disease: Hereditary Polycystic Kidney Disease," Amer. Journ. of Pathology 139:693-696 (1991) |
| ✓ | 195. | Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," Nature 362:841-844 (1993) |

| | |
|------------------------------|--|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|------------------------------|--|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|--|--|---|---------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Att. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Applicant: McSwiggen et al. | |
| (Use several sheets if necessary) | | Filing Date: September 18, 2003 | Group: |

| | | |
|----|------|--|
| AB | 196. | Koch et al., "Vascular Endothelial Growth Factor," Journal of Immunology 152:4149-4156 (1994) |
| | 197. | Kusser, "Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution," Reviews in Molecular Biotechnology 74:27-38 (2000) |
| | 198. | Kwak et al., "VEGF Is Major Stimulator in Model of Choroidal Neovascularization," Investigative Ophthalmology & Visual Science, 41(10), 3158-3164 (2000) |
| | 199. | Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," Chemical Reviews 95:2601-2627 (1995) |
| | 200. | Lasic and Papahadjopoulos, "Liposomes Revisited," Science 267:1275-1276 (1995) |
| | 201. | Lee and Larson, "Modified Liposome Formulations for Cytosolic Delivery of Macromolecules," ACS Symposium Series 752:184-192 (2000) |
| | 202. | Lee and Lee, "Preparation of Cluster Glycosides of N-Acetylgalactosamine That Have Subnanomolar Binding Constants Towards the Mammalian Hepatic Gal/GalNAc-specific Receptor," Glyconjugates J. 4:317-328 (1987) |
| | 203. | Lee et al., "Expression of Small Interfering RNA's Targeted Against HIV-1 rev Transcripts in Human Cells," Nature Biotechnology 19:500-505 (2002) |
| | 204. | Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," <i>Biochemical and Biophysical Research Communications</i> , 295, 744-748 (2002) |
| | 205. | Lepri et al., "Effect of Low Molecular Weight Heparan Sulphate on Angiogenesis in the Rat Cornea after Chemical Cauterization," Journal of Ocular Pharmacology 10:273-281 (1994) |
| | 206. | L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α -Lactalbumin mRNA Levels in C1271 Mouse," EMBO J. 11:4411-4418 (1992) |
| ✓ | 207. | Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," Methods Enzymol. 217:47-66 (1993) |

| | |
|---------------------------------|--------------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|---------------------------------|--------------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|--|---------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant: McSwiggen et al. | |
| | | Filing Date: September 18, 2003 | Group: |

| | | |
|----|------|---|
| AB | 208. | Limbach et al., "Summary: the modified nucleosides of RNA," <i>Nucleic Acids Research</i> 22(12):2183-2196 (1994) |
| | 209. | Lin and Matteucci, "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acid," <i>J. Am. Chem. Soc.</i> 120:8531-8532 (1998) |
| | 210. | Lin et al., "A Novel mRNA-crRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001) |
| | 211. | Lin et al., "Policing Rogue Genes", <i>Nature</i> 402:128-129 (1999) |
| | 212. | Liszewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:8000-8004 (1993) |
| | 213. | Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <i>J. Biol. Chem.</i> 270(42):24864-24870 (1995) |
| | 214. | Loakes, "The Applications of Universal DNA Base Analogues," <i>Nucleic Acids Research</i> 29:2437-2447 (2001) |
| | 215. | Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <i>Nucleic Acids Research</i> 21:2585-2589 (1993) |
| | 216. | Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <i>Biochemistry</i> 32:1751-1758 (1993) |
| | 217. | Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <i>Cell</i> 110:563-574 (2002) |
| | 218. | Maurer et al., "Lipid-based systems for the intracellular delivery of genetic drugs," <i>Molecular Membrane Biology</i> 16:129-140 (1999) |
| ✓ | 219. | McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <i>Nucleosides & Nucleotides</i> 10:287-290 (1991) |

| | |
|---------------------------------|-----------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|---------------------------------|-----------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|--|---------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant: McSwiggen et al. | |
| | | Filing Date: September 18, 2003 | Group: |

| | | |
|----|------|---|
| AB | 220. | McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," Proc. Natl. Acad. Sci. USA 83:399-403 (1986) |
| | 221. | McLaren et al., "Vascular Endothelial Growth Factor (VEGF) Concentrations are Elevated in Peritoneal Fluid of Women with Endometriosis," Human Reproduction 11:220-223 (1996) |
| | 222. | McLaren et al., "Vascular Endothelial Growth Factor is Produced by Peritoneal Fluid Macrophages in Endometriosis and Is Regulated by Ovarian Steroids," J. Clin. Invest. 98:482-489 (1996) |
| | 223. | McManus et al., "Gene Silencing Using Micro-RNA Designed Hairpins," RNA 8:842-850 (2002) |
| | 224. | Mesmaeker et al., "Novel Backbone Replacements for Oligonucleotides," American Chemical Society, pp. 24-39 (1994) |
| | 225. | Millauer et al., "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant," Letters to Nature 367:576-579 (1994) |
| | 226. | Miller et al., "Vascular Endothelial Growth Factor/Vascular Permeability Factor is Temporally and Spatially Correlated with Ocular Angiogenesis in a Primate Model," American Journal of Pathology 145:574-584 (1994) |
| | 227. | Miyagishi and Taira, "U6 Promoter-driven siRNAs with Four Uridine 3' Overhangs Efficiently Suppress Targeted Gene Expression in Mammalian Cells," Nature Biotechnology 19:497-500 (2002) |
| | 228. | Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," Science 256:992-996 (1992) |
| | 229. | Mori et al., "Inhibition of Choroidal Neovascularization by Intravenous Injection of Adenoviral Vectors Expressing Secretable Endostatin," American Journal of Pathology, 159(1), 313-320 (2001) |
| | 230. | Mori et al., "Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization," Journal of Cellular Physiology, 118(2) 253-263 (2001) |
| ✓ | 231. | Noonberg et al., In vivo generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation," Nucleic Acids Research 22(14):2830-2836 (1994) |

| | |
|---------------------------------|--------------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|---------------------------------|--------------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|--|--|---------------------------------------|-------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. | Serial No. |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | 02-742-F (400/132) | 10/665,951 |
| (Use several sheets if necessary) | | Applicant: McSwiggen et al. | |
| | | Filing Date: | Group: |
| | | September 18, 2003 | |

| | | |
|----|------|--|
| AB | 232. | Norby, "Angiogenesis: new aspects relating to its initiation and control," <i>APMIA</i> 105:417-437 (1997) |
| | 233. | Novina et al., "siRNA-Directed Inhibition of HIV-1 Infection," <i>Nature Medicine</i> 1-6 (2002) |
| | 234. | Nykanen et al., "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway," <i>Cell</i> 107:309-321 (2001) |
| | 235. | Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," <i>Nucleic Acids Symp. Ser.</i> 27:15-16 (1992) |
| | 236. | Ohno-Matsui, et al., "Inducible Expression of Vascular Endothelial Growth Factor in Adult Mice Causes Severe Proliferative Retinopathy and Retinal Detachment," <i>Animal Models from the Departments of Ophthalmology and Neuroscience and Molecular Biology and Genetics, Am. J. Pathology</i> , 160, 711-719 (2002) |
| | 237. | Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <i>Proc. Natl. Acad. Sci. USA</i> 89:10802-10806 (1992) |
| | 238. | Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <i>Biochimica et Biophysica Acta</i> 1238:86-90 (1995) |
| | 239. | Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <i>Biochemistry</i> 30:9914-9921 (1991) |
| | 240. | O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <i>Cell</i> 79:315-328 (1994) |
| | 241. | Orgis et al., "DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression," <i>AAPS PharmSci.</i> , 3 (3) article 21 (http://www.pharmsci.org) p. 1- 11 (2001) |
| | 242. | Ormerod et al., "Effects of Altering the Eicosanoid Precursor Pool on Neovascularization and Inflammation in the Alkali-burned Rabbit Cornea," <i>American Journal of Pathology</i> 137:1243-1252 (1990) |
| ↓ | 243. | Pal-Bhadra et al., "Heterochromatic Silencing and HP1 Localization in <i>Drosophila</i> Are Dependent on the RNAi Machinery," <i>Science</i> , 303, 669-672 (2004) |

| | |
|------------------------------|-----------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|------------------------------|-----------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|--|---------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | | |
| | | Applicant: McSwiggen et al. | |
| | | Filing Date: September 18, 2003 | Group: |

| | | |
|----|------|--|
| AB | 244. | Pandey et al., "Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- α -Induced Angiogenesis," Science 268:567-569 (1995) |
| | 245. | Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo," Proc. Natl. Acad. Sci. USA 92:5592-5596 (1995) |
| | 246. | Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," Molecular Cell 6:1077-1087 (2000) |
| | 247. | Passaniti et al., "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," Laboratory Investigation 67:519-528 (1992) |
| | 248. | Paul et al., "Effective Expression of Small Interfering RNA in Human Cells," Nature Biotechnology 20:505-508 (2002) |
| | 249. | Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," Nature 344:565-567 (1990) (often mistakenly listed as Perrault) |
| | 250. | Petersen et al., "Polyethylenimine-graft-Poly(ethylene glycol) Copolymers: Influence of Copolymer Block Structure on DNA Complexation and Biological Activities as Gene Delivery System," <i>Bioconjugate Chem.</i> , 13, 845-854 (2002) |
| | 251. | Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," Science 253:314-317 (1991) |
| | 252. | Pierce et al., "Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization," Proc. Natl. Acad. Sci. USA 92:905-909 (1995) |
| | 253. | Plate, "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas in vivo," Nature 359:845-848 (1992) |
| | 254. | Ponpipom et al., "Cell-Specific Ligands for Selective Drug Delivery to Tissues and Organs," J. Med. Chem. 24:1388-1395 (1981) |
| ✓ | 255. | Rajakumar et al., "Effects of Intrastriatal Infusion of D ₂ Receptor Antisense Oligonucleotide on Apomorphine-Induced Behaviors in the Rat," <i>Synapse</i> 26:199-208 (1997) |

| | |
|---------------------------------|--------------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|---------------------------------|--------------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|--|---------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant: McSwiggen et al. | |
| | | Filing Date: September 18, 2003 | Group: |

| | | |
|----|------|---|
| AB | 256. | Reich et al., "Small Interfering RNA (siRNA) targeting <i>VEGF</i> effectively inhibits ocular neovascularization in a mouse model," <i>Molecular Vision</i> , 9, 210-216 (2003) |
| | 257. | Reinhart and Bartel, "Small RNAs Correspond to Centromer Heterochromatic Repeats," <i>Science</i> 297:1831 (2002) |
| | 258. | Reinhart et al., "MicroRNAs in Plants," <i>Genes & Development</i> 16:1616-1626 (2002) |
| | 259. | Reynolds et al., "Rational siRNA design for RNA interference," <i>Nature Biotechnology</i> , 22, 3, 326-330 (2004) |
| | 260. | Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <i>J. Am. Chem. Soc.</i> 113:5109-5111 (1991) |
| | 261. | Saenger (ed), "Modified Nucleosides and Nucleotides; Nucleoside Di- and Triphosphates; Coenzymes and Antibiotics, (ch.7)" <i>Principles of Nucleic Acid Structure</i> 158-200 (1984) |
| | 262. | Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" <i>Science</i> 247:1222-1225 (1990) |
| | 263. | Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," <i>Proc. Natl. Acad. Sci. USA</i> 88:10591-10595 (1991) |
| | 264. | Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using β -cyanoethyl protected ribonucleoside phosphoramidites," <i>Nucl Acids Res.</i> 18:5433-5441 (1990) |
| | 265. | Schroeder et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," <i>Prog. Neuro-Psychopharmacol. & Biol. Psychiat.</i> 23:941-949 (1999) [sometimes cited by RPI as Prog Neuropsychopharmacol Biol Psychiatry 23:941-949, 1999] |
| | 266. | Schwarz et al., "Evidence that siRNAs Function as Guides, Not Primers, in the Drosophila and Human RNAi Pathways," <i>Molecular Cell</i> 10:537-548 (2002) |
| | 267. | Schwarz et al., "Asymmetry in the Assembly of the RNAi Enzyme Complex," <i>Cell</i> , 1115, 199-208 (2003) |
| ↓ | 268. | Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," <i>Nucleic Acids Research</i> 15:3113-3129 (1987) |

| | |
|---------------------------------|--------------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|---------------------------------|--------------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|--|---------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant: McSwiggen et al. | |
| | | Filing Date: September 18, 2003 | Group: |

| | | |
|----|------|---|
| AB | 269. | Senger et al., "Vascular permeability factor (VPF, VEGF) in tumor biology," <i>Cancer and Metastasis Reviews</i> 12:303-324 (1993) |
| | 270. | Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," <i>Nucleic Acids Research</i> 19:4247-4251 (1991) |
| | 271. | Sharp, Philip A., "RNAi and Double-strand RNA", <i>Genes and Development</i> 13:139-141 (1999) |
| | 272. | Sheehan et al., "Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides," <i>Nucleic Acids Research</i> , 31 (14), 4109-4118 (2003) |
| | 273. | Shifren et al., "Ovarian Steroid Regulation of Vascular Endothelial Growth Factor in the Human Endometrium: Implications for Angiogenesis during the Menstrual Cycle and in the Pathogenesis of Endometriosis," <i>The Journal of Clinical Endocrinology & Metabolism</i> 81:3112-3118 (1996) |
| | 274. | Shweiki et al., "Patterns of Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis," <i>J. Clin. Invest.</i> 91:2235-2243 (1993) |
| | 275. | Simantov et al., "Dopamine-Induced Apoptosis in Human Neuronal Cells: Inhibition by Nucleic Acids Antisense to the Dopamine Transporter," <i>Neuroscience</i> 74(1):39-50 (1996) |
| | 276. | Sommer et al., "The Spread and Uptake Pattern of Intracerebrally Administered Oligonucleotides in Nerve and Glial Cell Populations of the Rat Brain," <i>Antisense & Nucleic Acid Drug Development</i> 8:75-85 (1998) |
| | 277. | Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found" <i>Molecular Biology</i> , 286: 5441, p.886 (1999) |
| | 278. | Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," <i>Science</i> 262:1566-1569 (1993) |
| V | 279. | Sun, "Technology evaluation: SELEX, Giliad Sciences Inc," <i>Current Opinion in Molecular Therapeutics</i> 2:100-105 (2000) |

| | |
|------------------------------|-----------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|------------------------------|-----------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|--|--|--|-------------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Applicant: McSwiggen et al. | |
| (Use several sheets if necessary) | | Filing Date: September 18, 2003 | Group: |

| | | |
|----|------|---|
| AB | 280. | Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both in vitro in place of run-off and (G)-free transcriptions and in vivo as multi-sequences transcription vectors," <i>Nucleic Acids Research</i> 19:5125-5130 (1991) |
| | 281. | Takahashi et al., "Markedly Increased Amounts of Messenger RNAs for Vascular Endothelial Growth Factor and Placenta Growth Factor in Renal Cell Carcinoma Associated with Angiogenesis," <i>Cancer Research</i> 54:4233-4237 (1994) |
| | 282. | Thomas et al., "Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells," <i>PNAS</i> , 99, 14640-14645 (2002) |
| | 283. | Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter," <i>Nucleic Acids Research</i> 23:2259-2268 (1995) |
| | 284. | Turner et al., "Improved Parameters for Prediction of RNA Structure," <i>Cold Spring Harbor Symposia on Quantitative Biology Volume LII</i> , pp. 123-133 (1987) |
| | 285. | Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <i>J. Am. Chem. Soc.</i> 109:3783-3785 (1987) |
| | 286. | Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," <i>Genes & Development</i> 13:3191-3197 (1999) |
| | 287. | Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , 295, 3, 158-167 (2002) |
| | 288. | Tuschl, "RNA Interference and Small Interfering RNAs," <i>Chembiochem</i> 2:239-245 (2001) |
| | 289. | Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <i>Proc. Natl. Acad. Sci. USA</i> 96:7053-7058 (1999) |
| ↓ | 290. | Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <i>FEBS Letters</i> 421:280-284 (1998) |

| | |
|-------------------------------------|--|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|-------------------------------------|--|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|---|-------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. | Serial No. |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | 02-742-F (400/132) | 10/665,951 |
| | | Applicant: McSwiggen et al. | |
| | | Filing Date: September 18, 2003 | Group: |

| | | |
|----|------|---|
| AB | 291. | Uhlmann et al., "Studies on the Mechanism of Stabilization of Partially Phosphorothioated Oligonucleotides Against Nucleolytic Degradation," <u>Antisense & Nucleic Acid Drug Development</u> 7:345-350 (1997) |
| | 292. | Ui-Tei et al., "Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference," <u>Nucleic Acids Research</u> , 32, 3, 936-948 (2004) |
| | 293. | Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <u>TIBS</u> 17:334-339 (1992) |
| | 294. | Usman and McSwiggen, "Ch. 30 - Catalytic RNA (Ribozymes) as Drugs," <u>Annual Reports in Medicinal Chemistry</u> 30:285-294 (1995) |
| | 295. | Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an Escherichia coli Formylmethionine tRNA," <u>J. Am. Chem. Soc.</u> 109:7845-7854 (1987) |
| | 296. | Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," <u>Nucleic Acids Symposium Series</u> 31:163-164 (1994) |
| | 297. | Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," <u>Nucleic Acids Research</u> 21:3249-3255 (1993) |
| | 298. | Verdel et al., "RNAi-Mediated Targeting of Heterochromatin by the RITS Complex," <u>Science</u> , 303, 672-676 (2004) |
| | 299. | Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," <u>Annu. Rev. Biochem.</u> 67:99-134 (1998) |
| | 300. | Volpe et al., "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi," <u>Science</u> 297:1833-1837 (2002) |
| | 301. | Waterhouse, et al. "Virus Resistance and gene Silencing in Plants Can Be Induced by Simultaneous Expression of Sense and Antisense RNA" <u>Proc. Natl. Acad. Sci. USA</u> 99:13959-13964 (1998) |
| ✓ | 302. | Weckbecker et al., "Intradermal angiogenesis in nude mice induced by human tumor cells or b-FGF," <u>Angiogenesis Key Principles—Science—Technology—Medicine</u> pp296-301 (1992) |

| | |
|-------------------------------------|--|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|-------------------------------------|--|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|--|---------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant: McSwiggen et al. | |
| | Filing Date: September 18, 2003 | Group: | |

| | | |
|----|------|--|
| AB | 303. | Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4+ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," Journal of Virology 65:5531-5534 (1994) |
| | 304. | Wellstein and Czubayko, "Inhibition of Fibroblast Growth Factors," Breast Cancer Research and Treatment 38:109-119 (1996) |
| | 305. | Wianny and Zernicka-Goetz et al., "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development," Nature Cell Biology 2:70-75 (2000) |
| | 306. | Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," Nucleic Acids Research 23(14):2677-2684 (1995) |
| | 307. | Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," Methods in Molecular Biology 74:59-69 (1997) |
| | 308. | Woo et al., "Taxol Inhibits Progression of Congenital Polycystic Kindey Disease," Nature 368:750-753 (1994) |
| | 309. | Wu and Wu, "Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System," The Journ. of Biol. Chem. 262:4429-4432 (1987) |
| | 310. | Wu et al., "Cardiac Defects and Renal Failure in Mice with Targeted Mutations in Pkd2," Nature Genetics 24:75-78 (2000) |
| | 311. | Wu-Pong et al., "Nucleic Acid Drug Delivery, Part 2; Delivery to the Brain," 32-38 (1999) |
| | 312. | Yamada et al., "Nanoparticles for the delivery of genes and drugs to human hepatocytes," Published online: 29 June 2003, doi:10.1038/nbt843 (August 2003 Volume 21 Number 8 pp 885-890) (2003) |
| | 313. | Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993) |
| ✓ | 314. | Zamore et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," Cell 101:25-33 (2000) |

| | |
|---------------------------------|--------------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|---------------------------------|--------------------------------------|


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|--|---------------------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/132) | Serial No. 10/665,951 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant: McSwiggen et al. | |
| | | Filing Date: September 18, 2003 | Group: |

| | | |
|----|------|--|
| AB | 315. | Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," Mol. Cell. Biol. 10:4529-4537 (1990) |
| AB | 316. | Ziche et al., "Angiogenesis Can Be Stimulated or Repressed In Vivo by a Change in GM3:GD3 Ganglioside Ratio," Laboratory Investigation 67:711-715 (1992) |

| | |
|---------------------------------|--------------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|---------------------------------|--------------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | | |
|--|---|--|-------------------------------------|--|
| FORM PTO-1449 (Rev. 2-32) |  U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 02-742-F (400/131) | Serial No. 10/665,951 | |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Applicant: McSwiggen et al. | | |
| | | Filing Date: September 18, 2003 | Group: | |

U.S. PATENT APPLICATION DOCUMENTS

| Examiner Initial | | Document Number | Filing Date | Name | Class | Subclass | Publication Date if Appropriate |
|------------------|---|-----------------|-------------|------------------|-------|----------|---------------------------------|
| AB | * | US 2003/0190635 | 10/2003 | McSwiggen et al. | | | |
| AB | * | US 2003/0206887 | 11/2003 | Morrissey et al. | | | |

U.S. PATENT DOCUMENTS

| Examiner Initial | | Document Number | Date | Name | Class | Subclass | Filing Date if Appropriate |
|------------------|---|-----------------|----------|--------------|-------|----------|----------------------------|
| AB | * | 6,346,398 | 02/12/02 | Pavco et al. | | | |

FOREIGN PATENT DOCUMENTS

| | | Document Number | Date | Country | Class | Subclass | Translation | |
|----|---|-----------------|----------|---------------------------|-------|----------|-------------|----|
| | | | | | | | Yes | No |
| AB | * | 1325955 | 07/09/03 | EP (Klippel-Giese et al.) | | | | |
| AB | * | 08208687 | 08/1996 | JP (Hotoda et al.) | | | | |

| | |
|------------------------------|-----------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|------------------------------|-----------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-F
(400/131)

Serial No.

10/665,951

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

| | | | | | | | | |
|----|---|-----------|----------|-------------------------------|--|--|--|--|
| AB | * | 94/11499 | 05/26/94 | WO (Ullrich et al.) | | | | |
| | * | 94/21791 | 09/29/94 | WO (Bergmann et al.) | | | | |
| | * | 95/04142 | 02/09/95 | WO (Robinson) | | | | |
| | * | 95/13380 | 05/18/95 | WO (Draper et al.) | | | | |
| | * | 97/00957 | 01/09/97 | WO (Patterson-Winston et al.) | | | | |
| | * | 97/21808 | 06/19/97 | WO (Robinson) | | | | |
| | * | 99/04819 | 02/04/99 | WO (Klimuk et al.) | | | | |
| | * | 99/55857 | 11/04/99 | Wo (Beigelman et al.) | | | | |
| | * | 00/21560 | 04/20/00 | WO (Alitalo et al.) | | | | |
| | * | 01/097850 | 12/27/01 | WO (Siemeister et al.) | | | | |
| | * | 02/07747 | 01/31/02 | WO (King) | | | | |
| | * | 02/10378 | 02/07/02 | WO (Cowser et al.) | | | | |
| | * | 02/096927 | 12/05/02 | WO (Escobedo et al.) | | | | |
| | * | 03/068797 | 08/21/03 | WO (Rossi et al.) | | | | |
| | * | 03/070887 | 08/28/03 | WO (McSwiggen et al.) | | | | |
| | * | 03/070896 | 08/28/03 | WO (McSwiggen et al.) | | | | |
| | * | 03/070910 | 08/28/03 | WO (McSwiggen et al.) | | | | |
| | * | 03/074654 | 09/12/03 | WO (McSwiggen et al.) | | | | |
| | * | 03/080638 | 10/02/03 | WO (Lacasse et al.) | | | | |

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

| | | | |
|---|--|-------------------------|-------------------|
| FORM PTO-1449 (Rev. 2-32) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. | Serial No. |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | 02-742-F (400/131) | 10/665,951 |
| (Use several sheets if necessary) | | Applicant: | |
| | | McSwiggen et al. | |
| | | Filing Date: | Group: |
| | | September 18, 2003 | |

| | | | | | | | | |
|----|---|-----------|----------|-----------------------|--|--|--|--|
| AB | * | 04/009769 | 01/29/04 | WO (Tolentino et al.) | | | | |
| ↓ | * | 04/043977 | 05/27/04 | WO (Prakush et al.) | | | | |
| ↓ | * | 04/072261 | 08/26/04 | WO (Li et al.) | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

| | | |
|----|---|--|
| AB | * | Anderson et al., "Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance," <i>Oligonucleotides</i> , 13:303-312 (2003) |
| ↓ | * | Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglyceryl derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984) |
| ↓ | * | Hasan et al., "VEGF antagonists," <i>Oncologic, Metabolic & Endocrine</i> , 703-718 (2001) |
| ↓ | * | International Search Report for PCT/US03/05022 mailed January 6, 2005 |
| ↓ | * | International Search Report for PCT/US2004/016390 mailed March 31, 2005 |
| ↓ | * | International Search Report for PCT/US2004/027403 mailed July 12, 2005 |
| ↓ | * | International Search Report for PCT/US2004/030488 mailed January 12, 2005 |
| ↓ | * | Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> , 18:307-319 (2000) |
| ↓ | * | Kuwabara et al., "A C. elegans patched gene, ptc-1, functions in germ-line cytokinesis," <i>Genes and Development</i> , 14(15):1933-1944 (2000) |
| ↓ | * | Lu et al., "Tumor Inhibition By RNAi-Mediated VEGF an VEGFR2 Down Regulation in Xenograft Models," <i>Cancer Gene Therapy</i> , 10, Suppl. 1, S4-S5 (2003) |
| ↓ | * | Parry et al. 1999. "Bioactivity of anti-angiogenic ribozymes targeting <i>Flt-1</i> and <i>KDR</i> mRNA," <i>Nucleic Acid Res.</i> 27:2569-77 |

| | |
|------------------------------|-----------------------------------|
| EXAMINER /Amy Bowman/ | DATE CONSIDERED 06/08/2006 |
|------------------------------|-----------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-742-F
(400/131)

Serial No.

10/665,951

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

AB

*

Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (*flt*) closely related to the *fms* family," *Oncogene* 5:519-524 (1990)

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.